Latest AHA 2024 News
CLEAR SYNERGY: No Benefit with Routine Spironolactone in MI Patients
Key Takeaways: The CLEAR SYNERGY trial was a multicenter trial with a…
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran Associated with Durable Reductions in Serum TTR levels for ATTR -CM
Key Takeaways: A single dose of nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based therapy,…
SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity
Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among…
BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes
Key Points BPROAD was a randomized control trial in China that assigned…
Rivaroxaban Did Not Reduce Cognitive Decline and Stroke/TIA in Young AF Patients: BRAIN-AF Trial
Key Points: In patients with atrial fibrillation, it remains unclear if anticoagulation…